Table 4 Ongoing MEK inhibitors’ clinical trials in NSCLC
From: MEK inhibitors for the treatment of non-small cell lung cancer
Trial NCT number | Intervention | Cancer type | Phase | Status |
|---|---|---|---|---|
03170206 | Binimetinib + Palbociclib | KRAS-mutant NSCLC | I/II | Recruiting |
01859026 | Erlotinib + Binimetinib | KRAS- or EGFR-mutant NSCLC | I/IB | Active, not recruiting |
02185690 | Carboplatin + Pemetrexed + Binimetinib | NSCLC | I | Active, not recruiting |
02964689 | Cisplatin + Pemetrexed + Binimetinib | KRAS-mutant NSCLC | I | Active, not recruiting |
03581487 | Durvalumab + Selumetinib + Tremelimumab | NSCLC | I/II | Recruiting |
03991819 | Binimetinib + Pembrolizumab | NSCLC | I | Active, not recruiting |
01586624 | Selumetinib + Vandetanib | NSCLC | I | Active, not recruiting |
04526782 | Encorafenib + Binimetinib + Docetaxel | BRAF V600E-mutant NSCLC | II | Not yet recruiting |
01336634 | Dabrafenib + Trametinib | BRAF V600E-mutant NSCLC | II | Active, not recruiting |
04005144 | Brigatinib + Binimetinib | ALK or ROS1 rearranged NSCLC | I | Recruiting |
03087448 | Ceritinib + Trametinib | ALK-positive NSCLC | I/II | Recruiting |
01933932 | Selumetinib + Docetaxel | KRAS-mutant NSCLC | III | Active, not recruiting |
03600701 | Atezolizumab + Cobimetinib | NSCLC | II | Recruiting |
03202940 | Alectinib + Cobimetinib | ALK rearranged NSCLC | IB/II | Recruiting |
02642042 | Trametinib + Docetaxel | KRAS-mutant stage IV NSCLC | II | Active, not recruiting |
03299088 | Pembrolizumab + Trametinib | KRAS-mutant NSCLC | I | Recruiting |
03516214 | EGF816 + Trametinib | EGFR-mutant NSCLC | I | Recruiting |
03225664 | Trametinib + Pembrolizumab | NSCLC | I/II | Recruiting |
01750281 | Selumetinib + Docetaxel | NSCLC | II | Active, not recruiting |
02664935 | National Lung Matrix Trial: AZD4547/Vistusertib/Palbociclib/ Crizotinib/ Selumetinib/Docetaxel/AZD5363/ Osimertinib/ Durvalumab/ Sitravatinib/AZD6738 | NSCLC | II | Recruiting |
03990077 | HL-085 + Docetaxel | KRAS-mutant NSCLC | I | Not yet recruiting |
01912625 | Trametinib + Carboplatin + Paclitaxel + Radiation Therapy | NSCLC | I | Active, not recruiting |